HLX02: Innovation Could Overtake
The oncology treatment landscape in China is evolving rapidly as the government has prioritized access to innovative drugs to meet this significant...
705 Views
Shanghai Henlius (复宏汉霖) IPO: Not an Impressive Biosimilar Portfolio
Shanghai Henlius, a subsidiary of Fosun Pharma, is seeking to list in Hong Kong. In this insight, we will discuss the following topics: The...
1.3k Views
Fosun Tourism (1992.HK) Privatization - The Cancellation Price Is Not Good Enough
Fosun Tourism is on the rise after overcoming difficulties, with potential for share price to return to IPO level. Even if the Offer Price is...
628 Views